# The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

> **NCT07212933** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Gastric (Stomach) Cancer
- Biological Therapy
- Immunotherapy

## Interventions

- **BIOLOGICAL:** RetroNectin active Killer cells
- **DRUG:** TAS-102 (trifluridine and tipiracil, Lonsurf®)

## Key facts

- **NCT ID:** NCT07212933
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07212933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07212933, "The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07212933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*